Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV genotype 3 patients who achieve SVR with IFN-α 2a monotherapy

Digestive Diseases and Sciences

Volumn 56, Issue 11, 2011, Pages 3296-3304

  Amanzada, Ahmad ^a   Goralczyk, Armin ^a   Moriconi, Federico ^a   Blaschke, Martina ^a   Schaefer, Inga Marie ^a   Van Thiel, David ^b   Mihm, Sabine ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis C virus infection; Monotherapy; Ribavirin; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGE; ANEMIA; ARTICLE; DRUG RESPONSE; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; LEUKOPENIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STEATOSIS; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; YOUNG ADULT;

EID: 82555187925     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1933-2     Document Type: Article

References (46)

1. GL Davis JY Lau 1997 Factors predictive of a beneficial response to therapy of hepatitis C Hepatology 26 122S 127S 9305676 10.1002/hep.510260721 1:CAS:528:DyaK2sXmt1CktLw%3D (Pubitemid 27388084)
2. L Chemello P Bonetti L Cavalletto F Talato V Donadon P Casarin F Belussi M Frezza F Noventa P Pontisso 1995 Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group Hepatology 22 700 706 7657272 1:CAS:528:DyaK2MXoslartb4%3D
3. M Martinot-Peignoux P Marcellin M Pouteau C Castelnau N Boyer M Poliquin C Degott I Descombes B Le V Milotova 1995 Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C Hepatology 22 1050 1056 7557850 10.1002/hep.1840220406 1:CAS:528:DyaK2MXptl2jsrc%3D
4. KL Lindsay C Trepo T Heintges ML Shiffman SC Gordon JC Hoefs ER Schiff ZD Goodman M Laughlin R Yao JK Albrecht 2001 A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 395 403 11481625 10.1053/jhep.2001.26371 1:CAS:528:DC%2BD3MXmtVGqtLs%3D (Pubitemid 32702353)
5. S Zeuzem SV Feinman J Rasenack EJ Heathcote MY Lai E Gane J O'Grady J Reichen M Diago A Lin J Hoffman MJ Brunda 2000 Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 1666 1672 11106715 10.1056/NEJM200012073432301 1:CAS:528:DC%2BD3cXovVGhurY%3D
6. JG McHutchison SC Gordon ER Schiff ML Shiffman WM Lee VK Rustgi ZD Goodman MH Ling S Cort JK Albrecht 1998 Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1485 1492 9819446 10.1056/NEJM199811193392101 1:CAS:528:DyaK1cXnslGmtbs%3D (Pubitemid 28543496)
7. O Reichard G Norkrans A Fryden JH Braconier A Sonnerborg O Weiland 1998 Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group Lancet 351 83 87 9439491 10.1016/S0140-6736(97)06088-1 1:CAS:528:DyaK1cXmsFSqtw%3D%3D (Pubitemid 28026633)
8. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Goncales Jr D Haussinger M Diago G Carosi D Dhumeaux A Craxi A Lin J Hoffman Yu J 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 12324553 10.1056/NEJMoa020047 1:CAS:528: DC%2BD38Xnt12rtb0%3D
9. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar ZD Goodman K Koury M Ling JK Albrecht 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 965 11583749 10.1016/S0140-6736(01)06102-5 1:CAS:528:DC%2BD3MXntF2qtb8%3D (Pubitemid 32913521)
10. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin G Ramadori H Bodenheimer Jr D Bernstein M Rizzetto S Zeuzem PJ Pockros A Lin AM Ackrill 2004 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346 355 14996676 1:CAS:528:DC%2BD2cXitlOktrg%3D
11. ML Shiffman F Suter BR Bacon D Nelson H Harley R Sola SD Shafran K Barange A Lin A Soman S Zeuzem 2007 Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 N Engl J Med 357 124 134 17625124 10.1056/NEJMoa066403 1:CAS:528:DC%2BD2sXns12qurw%3D (Pubitemid 47057730)
12. O Dalgard K Bjoro KB Hellum B Myrvang S Ritland K Skaug N Raknerud H Bell 2004 Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study Hepatology 40 1260 1265 15558712 10.1002/hep.20467 1:CAS:528:DC%2BD2MXhslahsQ%3D%3D (Pubitemid 39656999)
13. P Ferenci H Brunner H Laferl TM Scherzer A Maieron M Strasser G Fischer H Hofer M Bischof R Stauber M Gschwantler P Steindl-Munda K Staufer K Loschenberger 2008 A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3 Hepatology 47 1816 1823 18454510 10.1002/hep.22262 1:CAS:528:DC%2BD1cXotVagsbY%3D (Pubitemid 351945549)
14. M Angelico B Koehler-Horst P Piccolo F Angelico S Gentile S Francioso P Tarquini RD Vecchia L Ponti G Pilleri A Barlattani A Grieco F Soccorsi P Guarascio L Demelia O Sorbello Z Rossi G Forlini S Zaru F Bandiera 2008 Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naive patients with chronic hepatitis C Eur J Gastroenterol Hepatol 20 680 687 18679072 10.1097/MEG. 0b013e3282f5196c 1:CAS:528:DC%2BD1cXotFags74%3D
15. M Yada A Masumoto N Yamashita K Motomura T Koyanagi S Sakamoto 2010 Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C World J Gastroenterol 16 1506 1511 20333792 10.3748/wjg.v16.i12.1506 1:CAS:528:DC%2BC3cXkt1CrsLg%3D
16. P Wietzke-Braun V Meier K Neubauer-Saile S Mihm G Ramadori 2005 Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients World J Gastroenterol 11 6188 6192 16273648 1:CAS:528:DC%2BD28XhsVentbs%3D (Pubitemid 43085063)
17. T Kumada H Toyoda T Honda T Kuzuya Y Katano I Nakano H Goto 2006 Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan Intervirology 49 112 118 16166799 10.1159/000087273 1:CAS:528:DC%2BD2MXhtVWntr%2FK (Pubitemid 41318186)
18. W Sievert GJ Dore GW McCaughan M Yoshihara DH Crawford W Cheng M Weltman W Rawlinson B Rizkalla JK Depamphilis SK Roberts 2011 Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1 Hepatology 53 1109 1117 21480317 10.1002/hep.24180 1:CAS:528:DC%2BC3MXktl2jurk%3D
19. N Reau SJ Hadziyannis D Messinger MW Fried DM Jensen 2008 Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin Am J Gastroenterol 103 1981 1988 18796095 10.1111/j.1572-0241.2008.01957.x 1:CAS:528:DC%2BD1cXhtFGhurrI
20. JL Kinzie PH Naylor MG Nathani RR Peleman MN Ehrinpreis M Lybik JR Turner JJ Janisse M Massanari MG Mutchnick 2001 African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians J Viral Hepat 8 264 269 11454177 10.1046/j.1365-2893. 2001.00292.x 1:STN:280:DC%2BD3Mvis1Sgsw%3D%3D (Pubitemid 32673737)
21. P Wietzke-Braun AB Maouzi LB Manhardt H Bickeboller G Ramadori S Mihm 2006 Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection Eur J Gastroenterol Hepatol 18 991 997 16894313 10.1097/01.meg.0000224478.89545.76 1:CAS:528:DC%2BD28Xnsl2htLg%3D (Pubitemid 44213043)
22. D Ge J Fellay AJ Thompson JS Simon KV Shianna TJ Urban EL Heinzen P Qiu AH Bertelsen AJ Muir M Sulkowski JG McHutchison DB Goldstein 2009 Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 399 401 19684573 10.1038/nature08309 1:CAS:528:DC%2BD1MXpvFCrtbw%3D
23. T Kawaoka CN Hayes W Ohishi H Ochi T Maekawa H Abe M Tsuge F Mitsui N Hiraga M Imamura S Takahashi M Kubo T Tsunoda Y Nakamura H Kumada K Chayama 2011 Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b J Hepatol 54 408 414 21112660 10.1016/j.jhep.2010.07.032 1:CAS:528:DC%2BC3MXit1yqtb4%3D
24. A Moghaddam E Melum N Reinton H Ring-Larsen H Verbaan K Bjoro O Dalgard 2011 IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection Hepatology 53 746 754 21374656 10.1002/hep.24154 1:CAS:528:DC%2BC3MXkt1Clsbk%3D
25. S Mihm A Fayyazi H Hartmann G Ramadori 1997 Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype Hepatology 25 735 739 9049227 10.1002/hep.510250340 1:STN:280:DyaK2s3gtFCnsw%3D%3D (Pubitemid 27106462)
26. S Mihm H Hartmann A Fayyazi G Ramadori 1996 Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio Dig Dis Sci 41 1256 1264 8654161 10.1007/BF02088246 1:STN:280:DyaK283lvVyrtw%3D%3D (Pubitemid 26227902)
27. VJ Desmet M Gerber JH Hoofnagle M Manns PJ Scheuer 1994 Classification of chronic hepatitis: diagnosis, grading and staging Hepatology 19 1513 1520 8188183 10.1002/hep.1840190629 1:STN:280:DyaK2c3ksFWisw%3D%3D (Pubitemid 24166476)
28. M Lagging N Langeland C Pedersen M Farkkila MR Buhl K Morch AP Dhillon A Alsio K Hellstrand J Westin G Norkrans 2008 Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection Hepatology 47 1837 1845 18454508 10.1002/hep.22253 1:CAS:528:DC%2BD1cXotVagtr4%3D (Pubitemid 351945551)
29. M von Wagner M Huber T Berg H Hinrichsen J Rasenack T Heintges A Bergk C Bernsmeier D Haussinger E Herrmann S Zeuzem 2005 Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C Gastroenterology 129 522 527 10.1053/j.gastro.2005.05.008 (Pubitemid 41096640)
30. M Manns S Zeuzem A Sood Y Lurie M Cornberg H Klinker P Buggisch M Rossle H Hinrichsen I Merican Y Ilan S Mauss S Abu-Mouch A Horban TH Muller C Welsch R Chen R Faruqi LD Pedicone H Wedemeyer 2011 Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C J Hepatol 55 554 563 21237227 10.1016/j.jhep.2010.12.024 1:CAS:528:DC%2BC3MXhtVGqur3K
31. T Tsunoda A Inui Y Etani Y Kiyohara T Sugiura K Ito R Miyazawa I Nagata S Ida T Fujisawa 2011 Efficacy of pegylated interferon-alpha2a monotherapy in Japanese children with chronic hepatitis C Hepatol Res 41 399 404 21518401 10.1111/j.1872-034X.2011.00789.x 1:CAS:528:DC%2BC3MXotFWhu78%3D
32. M Rodriguez-Torres LJ Jeffers MY Sheikh L Rossaro V Ankoma-Sey FM Hamzeh P Martin 2009 Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C N Engl J Med 360 257 267 19144941 10.1056/NEJMoa0805062 1:CAS:528:DC%2BD1MXnsFGitA%3D%3D
33. CH Liu CJ Liu CL Lin CC Liang SJ Hsu SS Yang CS Hsu TC Tseng CC Wang MY Lai JH Chen PJ Chen DS Chen JH Kao 2008 Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial Clin Infect Dis 47 1260 1269 18834319 10.1086/592579 1:CAS:528:DC%2BD1cXhsVeqs7jP
34. S Mihm M Monazahian S Grethe C Fechner G Ramadori R Thomssen 1999 Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infection J Med Virol 58 227 234 10447417 10.1002/(SICI)1096-9071(199907)58:3<227::AID-JMV7>3.0.CO;2-7 1:CAS:528:DyaK1MXjvFKhur8%3D (Pubitemid 29278024)
35. JA Mata-Marin JL Fuentes-Allen J Gaytan-Martinez B Manjarrez-Tellez A Chaparro-Sanchez CI Arroyo-Anduiza 2009 APRI as a predictor of early viral response in chronic hepatitis C patients World J Gastroenterol 15 4923 4927 19842223 10.3748/wjg.15.4923 1:CAS:528:DC%2BD1MXhtlCiu7zL
36. HP Verbaan HE Widell TL Bondeson SC Lindgren 2002 High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin Eur J Gastroenterol Hepatol 14 627 633 12072596 10.1097/00042737-200206000-00007 1:CAS:528:DC%2BD38XlsF2js7s%3D (Pubitemid 34666641)
37. V Suppiah M Moldovan G Ahlenstiel T Berg M Weltman ML Abate M Bassendine U Spengler GJ Dore E Powell S Riordan D Sheridan A Smedile V Fragomeli T Muller M Bahlo GJ Stewart DR Booth J George 2009 IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 1100 1104 19749758 10.1038/ng.447 1:CAS:528:DC%2BD1MXhtFaju7%2FM
38. Y Tanaka N Nishida M Sugiyama M Kurosaki K Matsuura N Sakamoto M Nakagawa M Korenaga K Hino S Hige Y Ito E Mita E Tanaka S Mochida Y Murawaki M Honda A Sakai Y Hiasa S Nishiguchi A Koike I Sakaida M Imamura K Ito K Yano N Masaki F Sugauchi N Izumi K Tokunaga M Mizokami 2009 Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 1105 1109 19749757 10.1038/ng.449 1:CAS:528: DC%2BD1MXhtFaju73K
39. ML Yu CF Huang JF Huang NC Chang JF Yang ZY Lin SC Chen MY Hsieh LY Wang WY Chang YN Li MS Wu CY Dai SH Juo WL Chuang 2011 Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients Hepatology 53 7 13 21254157 10.1002/hep.23976 1:CAS:528:DC%2BC3MXitVeksrw%3D
40. N Sakamoto M Nakagawa Y Tanaka Y Sekine-Osajima M Ueyama M Kurosaki N Nishida A Tamori NS Yuki Y Itsui S Azuma S Kakinuma S Hige Y Itoh E Tanaka Y Hiasa N Izumi K Tokunaga M Mizokami M Watanabe 2011 Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b J Med Virol 83 871 878 21360545 10.1002/jmv.22038 1:CAS:528:DC%2BC3MXkvVyrtrw%3D
41. TM Scherzer H Hofer AF Staettermayer K Rutter S Beinhardt P Steindl-Munda H Kerschner HH Kessler P Ferenci 2011 Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin J Hepatol 54 866 871 21145807 10.1016/j.jhep.2010.08.024 1:CAS:528:DC%2BC3MXkvFGhurg%3D
42. AU Neumann NP Lam H Dahari DR Gretch TE Wiley TJ Layden AS Perelson 1998 Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 103 107 9756471 10.1126/science.282.5386. 103 1:CAS:528:DyaK1cXmsFOjsLc%3D (Pubitemid 28471138)
43. NP Lam AU Neumann DR Gretch TE Wiley AS Perelson TJ Layden 1997 Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa Hepatology 26 226 231 9214474 10.1002/hep.510260130 1:CAS:528: DyaK2sXkslagtbo%3D (Pubitemid 27280329)
44. K Bjoro H Bell B Myrvang K Skaug N Raknerud P Sandvei S Storseth S Ritland S Lund-Tonnesen A Bucher KB Hellum 2002 Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study Scand J Gastroenterol 37 344 349 11916198 10.1080/003655202317284264 1:CAS:528:DC%2BD38XislClsb4%3D (Pubitemid 34194822)
45. N Akuta F Suzuki A Tsubota Y Suzuki T Someya M Kobayashi S Saitoh Y Arase K Ikeda H Kumada 2002 Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors J Hepatol 37 831 836 12445425 10.1016/S0168-8278(02) 00301-X 1:CAS:528:DC%2BD38XoslCjtbs%3D (Pubitemid 35404223)
46. O Yokosuka S Iwama N Suzuki M Takashi Y Hirai K Uchiumi M Kimura N Gotou S Hino A Hayasaka T Kanda S Kawai K Fukai F Imazeki H Saisho 2004 High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective study Intervirology 47 328 334 15564744 10.1159/000080876 1:CAS:528:DC%2BD2cXhtVagsbbK (Pubitemid 39541279)